cover image: CADTH REIMBURSEMENT REVIEW - Patient and Clinician Group Input - inebilizumab (Uplizna)


CADTH REIMBURSEMENT REVIEW - Patient and Clinician Group Input - inebilizumab (Uplizna)

18 Apr 2024

Attacks to the optic nerves produce swelling and inflammation that cause symptoms of pain and loss of vision while damage to the spinal cord causes weakness or paralysis in the legs or arms, loss of sensation, and problems with bladder and bowel function. [...] Adherence improves the clinical benefit of the medication and the quality of life of the individual, resulting in a potential decrease of burden to the Canadian health and social systems. [...] • Treatment with inebilizumab has the potential to allow people living with NMOSD to remain in the workforce, sustain family and social roles and responsibilities longer, improve their quality of life, decrease the need for caregiving (family caregiver or paid caregiver) and reduce the financial burden to health and social systems. [...] Around 54% of the respondents were between 35 and 54 years of age, approximately 32% were between the ages of 55 and 74, and 25% of the patients were between the ages of 25 and 34. [...] NMOSD Attacks: Around 38% of the survey responders reported receiving a diagnosis less than three months after their first attack or onset of symptoms, and more than 20% of the survey respondents waited for more than five years to receive a diagnosis following first visible symptoms or attack Attacks are the hallmark of NMOSD and the frequency of those attacks, as reported by patients and caregive.
Published in

Table of Contents